Sun Pharma Advanced Research Company profitability ratios
Per cent unless marked ×
| Tap a line for its trend | Last 12Mto Jun 2026 | FY26Mar 2026 | FY25Mar 2025 | FY24Mar 2024 | FY22 and earlierAlpha Plus |
|---|
Returns | FY22 and earlierEvery year the company has filed comes with Alpha Plus. | ||||
|---|---|---|---|---|---|
| 277.4% | 277.4% | 751.5% | −121.3% | ||
| 123.9% | 123.9% | −80.5% | −57.6% | ||
| 230.6% | 230.6% | −317.6% | −92.0% | ||
| 84.9% | 83.9% | −853.5% | −250.3% | ||
Margins | |||||
| 84.7% | 85.1% | −450.2% | −532.2% | ||
| 84.5% | 84.5% | −467.5% | −548.8% | ||
| — | 106.5% | −2,092.1% | — | ||
| 83.0% | 82.6% | −477.6% | −512.0% | ||
| 83.0% | 82.7% | −477.2% | −512.5% | ||
| — | 82.8% | −477.5% | — | ||
| −14.0% | −14.0% | −516.4% | −603.2% | ||
Additional | |||||
| −0.0% | −0.0% | 0.1% | −0.1% | ||
| 277.4% | 277.4% | 751.5% | −121.3% | ||
From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.